Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer

被引：0
|
作者：
Shen, Yijun
Peng, Liangju
Xu, Peihang
Wang, Yanhao
Wang, Xiang
Yao Xudong
Liu, Yushan
Ye, Ding-Wei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China
[3] Tongji Univ, Shanghai Tenth Peoples Hosp, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Biomedical markers of response to intravesical BCG treatment in high-risk non-muscle invasive bladder cancer
    Jallad, S.
    Thomas, P.
    Newport, M.
    Kern, F.
    BRITISH JOURNAL OF SURGERY, 2014, 101 : 66 - 67
  • [22] Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
    Narayan, V.
    Boorjian, S.
    Alemozaffer, M.
    Konety, B. R.
    Gomella, L.
    Kamat, A. M.
    Lerner, S. P.
    Svatek, R. S.
    Karsh, L.
    Canter, D.
    Lotan, Y.
    Inman, B. A.
    Yang, M.
    Garcia-Horton, V.
    Sawutz, D.
    Parker, N.
    Dinney, C. P. N.
    EUROPEAN UROLOGY, 2021, 79 : S1026 - S1027
  • [23] COMBINATION REGIMEN OF INTRAVESICAL DOCETAXEL, GEMCITABINE, AND CISPLATIN IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
    Joffe, Benjamin I.
    Christin, John R.
    Le Coz, Clementine
    Pak, Jamie S.
    Laplaca, Caroline
    Reyes, Helena Vila
    DeCastro, G. Joel
    Anderson, Christopher B.
    Abate-Shen, Cory
    McKiernan, James M.
    Lenis, Andrew T.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E247 - E248
  • [24] A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder
    DeCastro, G. J.
    Stein, M.
    Abate-Shen, C.
    Miles, C.
    Gray, J.
    Joffe, B.
    Anderson, C.
    Lenis, A.
    McKiernan, J. M. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1143 - S1143
  • [25] Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024
    Qu, Feng
    Darji, Saloni
    Thompson, David H.
    PHARMACEUTICS, 2024, 16 (09)
  • [26] PHASE 3 STUDY OF VICINEUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH RESULTS
    O'Donnell, Michael
    Shore, Neal
    Keane, Thomas
    Jewett, Michael
    Dickstein, Rian
    Wolk, Fred
    Dillon, Rachelle L.
    Cizeau, Jeannick
    Kassouf, Wassim
    JOURNAL OF UROLOGY, 2021, 206 : E296 - E297
  • [27] PATIENT PREFERENCES FOR TREATMENT OF BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: A DISCRETE CHOICE EXPERIMENT
    Collacott, H.
    Rentz, A.
    Krucien, N.
    Heidenreich, S.
    Ghatnekar, O.
    VALUE IN HEALTH, 2022, 25 (07) : S298 - S299
  • [28] SEQUENTIAL INTRAVESICAL GEMCITABINE AND DOCETAXEL FOR BCG-NAIVE HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
    McElree, Ian M.
    Steinberg, Ryan L.
    Martin, Alexander C.
    Richards, Jordan
    Mott, Sarah L.
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E488 - E488
  • [29] Intravesical BCG therapy for non-muscle invasive bladder cancer
    Figurin, K. M.
    ONKOUROLOGIYA, 2012, 8 (01): : 14 - 22
  • [30] An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer
    Khene, Zine-Eddine
    Lotan, Yair
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (06) : 415 - 423
12345